Physician profile
Bascom C Raney
NPI 1720083876
$2,858.72
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $878 · 2021: $888 · 2022: $27.53.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $468.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $365.06 | 2019-2021 | |
| Novo Nordisk INC | $322.13 | 2019-2022 | |
| Amgen INC. | $205.80 | 2019-2021 | |
| Lilly USA, LLC | $171.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $158.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $156.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.20 | 2020-2021 | |
| Amarin Pharma, INC. | $131.42 | 2019-2020 | |
| Pfizer INC. | $116.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $88.37 | 2019-2021 | |
| Allergan, INC. | $81.67 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $79.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.93 | 2019-2021 | |
| Abbvie INC. | $60.54 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.28 | 2019 | |
| Astellas Pharma US INC | $44.01 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $29.73 | 2021 | |
| Abbott Laboratories | $24.91 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.05 | 2020 | |
| Esperion Therapeutics, INC. | $22.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.17 | 2019 | |
| Boston Scientific Corporation | $17.26 | 2021 | |
| Cardiovascular Systems INC. | $15.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bascom Raney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.